The strong Q2 beat and raised full-year guidance, combined with improving leverage metrics and a key FDA MRTP authorization for ZYN, reinforce the smoke-free transition thesis. Traders should watch for continued IQOS momentum outside Japan/Poland and the impact of accelerated U.S. investments in H2, which could pressure near-term margins but support long-term brand value. The Q3 guidance of $2.20-$2.25 provides a clear near-term catalyst.
Price Chart
Executive Summary
PMI reported Q2 2026 adjusted diluted EPS of $2.20, a 15.2% increase YoY and well above the $2.04 consensus, driven by strong smoke-free revenue growth (up 11.7% reported, 9.7% organically) and robust pricing in combustibles. However, reported GAAP EPS fell 7.7% to $1.80 due to a $511M non-cash impairment of its RBH equity investment. The company updated its full-year adjusted EPS forecast to $8.26-$8.41, representing 9.5%-11.5% growth, and guided Q3 adjusted EPS of $2.20-$2.25, both above current Street expectations, reinforcing a positive operational trajectory despite currency headwinds.
Key Financial Metrics
Key Facts
- Q2 2026 adjusted diluted EPS of $2.20 grew 15.2% YoY, beating the $2.04 consensus.
- Total net revenues reached a record $11.2 billion, up 10.4% reported (7.6% organically), with smoke-free now ~42% of total.
- Full-year 2026 adjusted diluted EPS forecast raised to $8.26-$8.41 (9.5%-11.5% growth), above the prior implied consensus.
- Q3 2026 adjusted EPS guided to $2.20-$2.25, above the $2.04 consensus for the next quarter.
- Reported GAAP EPS fell 7.7% to $1.80 due to a $511M non-cash impairment of the RBH (Canada) equity investment.
- International Smoke-Free segment net revenues grew 14.2% (11.8% organically), driven by 8.0% volume growth and strong IQOS performance.
- Net debt to adjusted EBITDA improved to 2.35x from 2.53x at year-end 2025, targeting ~2.0x by year-end.
- FDA granted MRTP authorization to 20 ZYN variants on June 30, the first and only for a nicotine pouch product.
Financial Impact
Q2 adjusted EPS beat consensus by ~7.8% ($2.20 vs $2.04), with full-year guidance raised to $8.26-$8.41, implying ~$0.22 above the prior implied consensus at the midpoint.
Risk Factors
- Currency headwinds: full-year currency impact revised to $0.15 favorable (down from $0.20), with Q3 expected to face an $0.08 unfavorable impact.
- U.S. segment weakness: net revenues declined 0.7% in Q2 and 16.1% YTD, with adjusted OCI down 19.1% organically in Q2 due to investments and manufacturing costs.
- Japan and Poland headwinds: excise-driven price increases in Japan and a flavor ban in Poland are creating transient volume pressure on IQOS HTU.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-049107 |
| Document: earningsreleasepm-ex991xq2.htm | 0001628280-26-049107 |
| Document: pm-20260722.htm | 0001628280-26-049107 |
| Document: 0001628280-26-049107-index-headers.html | 0001628280-26-049107 |
| Document: 0001628280-26-049107-index.html | 0001628280-26-049107 |
| Document: 0001628280-26-049107.txt | 0001628280-26-049107 |
| 8-K Data (Synthetic) | 0001628280-26-049107 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 8, 2026 24d ago | 8-K | $184.73 $194.86 | ▲ +5.48% | ▲ +6.15% | $187.32 (+1.40%) |
Aug 24, 2026 5w ago | 8-K | $191.46 $187.30 | ▼ −2.17% | ▼ −2.64% | $187.32 (−2.16%) |
Aug 3, 2026 8w ago | 25-NSE | $187.41 $186.00 | ▼ −0.75% | ▼ −2.78% | $187.32 (−0.05%) |
Jul 22, 2026 10w ago | 8-K | $194.30 $198.44 | ▲ +2.13% | ▲ +4.53% | $187.32 (−3.59%) |
Jun 29, 2026 13w ago | 8-K | $180.91 $184.76 | ▲ +2.13% | ▲ +1.52% | $187.32 (+3.54%) |
Jun 11, 2026 16w ago | 8-K | $180.77 $179.44 | ▼ −0.74% | ▼ −1.17% | $187.32 (+3.62%) |
May 20, 2026 19w ago | 8-K | $187.72 $178.51 | ▼ −4.91% | ▼ −6.71% | $187.32 (−0.21%) |
May 6, 2026 21w ago | 8-K | $170.38 $186.93 | ▲ +9.72% | ▲ +8.58% | $187.32 (+9.94%) |
Apr 22, 2026 23w ago | 8-K | $163.52 $163.68 | ▲ +0.10% | ▲ +0.04% | $187.32 (+14.56%) |
Mar 13, 2026 29w ago | 8-K | $173.11 $163.04 | ▼ −5.82% | ▼ −3.70% | $187.32 (+8.21%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access